An interventional study of Veneze peptide hair serum and Topical minoxidil in Androgenetic Alopecia (AGA), sponsored by Institute of Dermatology, Thailand. Recruiting at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Institute of Dermatology, Thailand · Not applicable, Interventional, and Treatment
This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
Androgenetic alopecia (AGA) is a common condition affecting both men and women and can significantly impact quality of life. Topical minoxidil is a widely used treatment; however, its effectiveness varies and it may cause local adverse effects in some patients. Peptide hair serums have emerged as a potential alternative, with proposed mechanisms including stimulation of hair follicle activity and promotion of hair growth.
This study aims to evaluate the efficacy and safety of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. The primary objective is to assess improvement in hair growth, including changes in hair density and hair thickness. Secondary objectives include evaluation of safety, tolerability, and patient-reported outcomes.
This is a randomized, double-blind, parallel-group study. Eligible participants with androgenetic alopecia will be randomly assigned to receive either the peptide-based hair serum or topical minoxidil. Treatments will be administered according to the study protocol over a defined study period.
Efficacy outcomes will include quantitative assessment of hair density and hair thickness. Safety will be evaluated through monitoring of adverse events and local tolerability.
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's planned enrollment of 80 is above the median of 50 across 430 interventional studies indexed under Alopecia.
Browse Alopecia studies →Institute of Dermatology, Thailand is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hair and scalp-related exclusions:
Medication-related exclusions:
Use within 6 months prior to screening of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive the VENEZE peptide factor hair serum applied topically to the scalp for 24 weeks.
Other: Veneze peptide hair serum
Participants in this arm will receive 2% minoxidil solution applied topically to the scalp for 24 weeks.
Drug: Topical minoxidil
Participants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol
Also known as: Hair growth peptide serum
Topical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.
Also known as: Topical Minoxidil 2% solution
Change in hair density from baseline
Change from baseline in hair count within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
Time frame: 12 and 24 weeks
Change in hair diameter and terminal hair count from baseline
Change from baseline in hair diameter and the number of terminal hairs within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
Time frame: 12 and 24 weeks
Investigator Global Aesthetic Improvement Scale
Investigator assessment of treatment response using the Global Aesthetic Improvement Scale at the vertex and frontal scalp regions at baseline, week 12, and week 24.
Time frame: 12 and 24 weeks
Change in androgenetic alopecia severity
Change in AGA severity based on Norwood-Hamilton classification in males and Ludwig classification in females at baseline, week 12, and week 24.
Time frame: 12 and 24 weeks
Patient Global Assessment of hair growth
Change in patient-reported hair growth and satisfaction assessed using Patient Global Assessment (PGA) and Hair Growth Questionnaire scores at baseline, week 12, and week 24.
Time frame: 12 and 24 weeks
Incidence of adverse events
Incidence and severity of treatment-related adverse events recorded from baseline until the end of the study.
Time frame: 24 weeks
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 6 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Dermatology, Thailand